THE USE OF PROBIOTICS IN THE PRACTICE OF A THERAPIST


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article analyzes the terminological interpretation of changes of intestinal microbiota in health and disease. The role of the microbiota in vital metabolic processes in the human body is discussed. Characteristics of probiotics and their importance in the therapy of socially significant diseases are given. The special role of probiotics in the prevention of antibioticassociated lesions of the digestive tract is emphasized.

全文:

受限制的访问

作者简介

Mikhail Osadchuk

I.M. Sechenov First Moscow State Medical University

Email: osadchuk.mikhail@yandex.ru
MD, Professor, Head of the Department of Polyclinic Therapy 119991, Moscow, 8 Malaya Trubetskaya St

Dmitry Balashov

I.M. Sechenov First Moscow State Medical University; City Hospital № 52

Email: d-balashov@yandex.ru
PhD, Associate Professor of the Department of Polyclinic Therapy; Chief Physician 119991, Moscow, 8 Malaya Trubetskaya St

Maksim Osadchuk

City Hospital № 52

Email: maxlife2004@mail.ru
PhD, Head of the Department of organizational-methodological and clinical-expert work 117546, Moscow, 7/1 Medynskaya St

参考

  1. Комаров Ф.И., Осадчук М.А., Осадчук А.М. Практическая гастроэнтерология. М.: Медицинское информационное агентство, 2010. 480 с
  2. Nissle A. Über die Grundlagen einer neuen ursächlichen Bekämpfung der pathologischen Darmflora. In: Deutsche Medizinische Wochenschrift. 1916;42:1181-4.
  3. Бондаренко В.М., Мацулевич Т.В. Дисбактериоз кишечника как клинико-лабораторный синдром: современное состояние проблемы. М.: ГЭОТАР-Медиа, 2007. 304 с.
  4. Gupta A., Chey W.D. Breath testing for small intestinal bacterial overgrowth: a means to enrich rifaximin responders in ibs patients? Am. J. Gastroenterol. 2016;111 (3):305-6.
  5. Салливан А., Норд К. Место пробиотиков в терапии инфекций желудочно-кишечного тракта у человека. Клин. микробиол. 2003;5:280-5.
  6. Moloney R.D., Desbonnet L., Clarke G., Dinan T.G., Cryan J.F. The microbiome: stress, health and disease. Mamm. Genome. 2014;25:49-74.
  7. O'Mahony S.M., Hyland N.P., Dinan T.G., Cryan J.F. Maternal separation as a model of brain-gut axis dysfunction. Psychopharmacology (Berl). 2011;214:71-88.
  8. Mayer E.A. Gut feelings: the emerging biology of gut-brain communication. Nat. Rev. Neurosci. 2011 ; 12:453-66.
  9. Grenham S., Clarke G., Cryan J., Dinan T.G. Brain-gut-microbe communication in health and disease. Frontiers in Gastrointestinal Science. 2011: In Press beyond intestinal disorders. World J. Gastroenterol. 2015;21(1):102-11.
  10. Murphy E.F., Cotter P.D., Healy S., Marques T.M., O'Sullivan O., Fouhy F., Clarke S.F., O'Toole P.W., Quigley E.M., Stanton C. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut. 2010;59:1635-42.
  11. Parks B.W., Nam E., Org E., Kostem E., Norheim F., Hui S.T., Pan C., Civelek M., Rau C.D., Bennett B.J. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell Metab. 2013;17:141-52.
  12. Teixeira T.F., Collado M.C., Ferreira C.L., Bressan J., Peluzio Mdo C. Potential mechanisms for the emerging link between obesity and increased intestinal permeability. Nutr. Res. 2012;32:637-47.
  13. Kootte R.S., Vrieze A., Holleman F., Dallinga-Thie G.M., Zoetendal E.G., de Vos W.M., Groen A.K., Hoekstra J.B., Stroes E.S., Nieuwdorp M. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes. Metab. 2012;14:112-20.
  14. Traseid M., Manner I.W., Pedersen K.K., Haissman J.M., Kvale D., Nielsen S.D. Microbial translocation and cardiometabolic risk factors in HIV infection. AIDS Res Hum Retroviruses. 2014;30:514-22. 41
  15. Wang Z., Klipfell E., Bennett B.J., Koeth R., Levison B.S., Dugar B., Feldstein A.E., Britt E.B., Fu X., Chung Y.M. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57-63.
  16. Tuohy K.M., Fava F., Viola R. The way to a man's heart is through his gut microbiota - dietary pro- and prebiotics for the management of cardiovascular risk. Proc. Nutr. Soc. 2014;73:172-85.
  17. Tang W.H., Wang Z., Levison B.S., Koeth R.A., Britt E.B., Fu X., Wu Y., Hazen S.L. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 2013;368:1575-84.
  18. Koeth R.A., Wang Z., Levison B.S., Buffa J.A., Org E., Sheehy B.T., Britt E.B., Fu X., Wu Y., Li L. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 2013;19:576-85.
  19. Wang Z., Tang W.H., Buffa J.A., Fu X., Britt E.B., Koeth R.A., Levison B.S., Fan Y., Wu Y., Hazen S.L. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur. Heart J. 2014;35:904-10.
  20. Le Roy T., Llopis M., Lepage P., Bruneau A., Rabot S., Bevilacqua C., Martin P., Philippe C., Walker F., Bado A. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013;62:1787-94.
  21. Delzenne N.M., Cani P.D. Interaction between obesity and the gut microbiota: relevance in nutrition. Annu. Rev. Nutr. 2011 ;31:15-31.
  22. Bugianesi E., Moscatiello S., Ciaravella M.F., Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr. Pharm. Des. 2010;16:1941-51.
  23. van Best N., Jansen P.L., Rensen S.S. Rensencorresponding author. The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation. Hepatol. Int. 2015;9(3):406-15.
  24. Schnabl B., Brenner D.A. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146:1513-24.
  25. Rabot S., Membrez M., Bruneau A., Gérard P., Harach T., Moser M., Raymond F., Mansourian R., Chou C.J. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J. 2010;24:4948-59.
  26. Frémont M., Coomans D., Massart S., De Meirleir K. High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients. Anaerobe. 2013;22:50-6.
  27. Borody T.J., Nowak A., Finlayson S. The GI microbiome and its role in chronic fatigue syndrome: A summary of bacteriotherapy. J. Australas. Coll. Nutr. Env. Med. 2012;31:3.
  28. Reynolds L.A., Finlay B.B. A case for antibiotic perturbation of the microbiota leading to allergy development. Expert Rev. Clin. Immunol. 2013;9:1019-30.
  29. Strachan D.P. Hay fever, hygiene, and household size. BMJ. 1989;299:1259-60.
  30. Noverr M.C., Huffnagle G.B. The ‘microflora hypothesis' of allergic diseases. Clin. Exp. Allergy. 2005;35:1511-20.
  31. Olszak T., An D., Zeissig S., Vera M.P., Richter J., Franke A., Glickman J.N., Siebert R., Baron R.M., Kasper D.L. Microbial exposure during early life has persistent effects on natural killer T cell function. Science. 2012;336:489-93.
  32. Stensballe L.G., Simonsen J., Jensen S.M., Bennelykke K., Bisgaard H. Use of antibiotics during pregnancy increases the risk of asthma in early childhood. J. Pediatr. 2013;162:832-8.
  33. Goksör E., Alm B., Pettersson R., Möllborg P., Erdes L., Aberg N., Wennergren G. Early fish introduction and neonatal antibiotics affect the risk of asthma into school age. Pediatr. Allergy Immunol. 2013;24:339-44.
  34. Jang S.O., Kim H.J., Kim Y.J., Kang M.J., Kwon J.W., Seo J.H., Kim H.Y., Kim B.J., Yu J., Hong S.J. Asthma prevention by lactobacillus rhamnosus in a mouse model is associated With CD4(+)CD25(+)Foxp3(+) T Cells. Allergy Asthma Immunol. Res. 2012;4:150-6.
  35. Fiocchi A., Burks W., Bahna S.L., Bielory L., Boyle R.J., Cocco R., Dreborg S., Goodman R., Kuitunen M., Haahtela T. Clinical Use of Probiotics in Pediatric Allergy (CUPPA): A World Allergy Organization Position Paper. World Allergy Organ. J. 2012;5:148-67.
  36. Шендеров Б.А. Медицинская микробная экология и функциональное питание.-Москва, 2001.
  37. Rosa R.M., Ferrari Mde L., Pedrosa M.S., Ribeiro G.M., Brasileiro-Filho G., Cunha A.S. Correlation of endoscopic and histological features in adults with suspected celiac disease in a referral center of minas gerais. Brazil. Arq Gastroenterol. 2014;51 (4):290-6.
  38. Осадчук М.А., Осадчук М.М. Синдром раздраженного кишечника и микробиота: пути оптимизации терапии. Врач. 2015;5:47-51.
  39. Lilly D.M., Stillwell R.H. Probiotics: Growth promoting factors produced by microorganisms. Science. 1965;147:747-8.
  40. Румянцев В.Г. Пробиотики: перспективы лечебного применения при воспалительных заболеваниях кишечника. Фарматека. 2009;13:77-9.
  41. Малов В.А., Гюлазян Н.М. Микробиоценоз желудочно-кишечного тракта: современное состояние проблемы. Лечащий врач. 2007;6:24-8
  42. Kumar S., Singhi S. Role of probiotics in prevention of Candida infection in critically ill children. Mycoses. 2013;56(3):204-11.
  43. Vandenplas Y., Huys G., Daube G. Probiotics: an update. J. Pediatr. (Rio J). 2015;91 (1) :6-21.
  44. Singhi S.C., Kumar S. Probiotics in critically ill children. Published online 2016 Mar 29. doi: 10.12688/f1000research.7630.
  45. Langdon A., Crook N., Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 2016;8:39.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##